2-Phenylethynesulfonamide (PES) uncovers a necrotic process regulated by oxidative stress and p53.

Paolo Mattiolo, Ares Barbero-Farran, Víctor J Yuste, Jacint Boix, Judit Ribas

Journal: Biochemical pharmacology 2015;91(3):301-11

PMID: 25139326

Abstract

2-Phenylethynesulfonamide (PES) or pifithrin-μ is a promising anticancer agent with preferential toxicity for cancer cells. The type of cell death and the molecular cascades activated by this compound are controversial. Here, we demonstrate PES elicits a caspase- and BAX/BAK-independent non-necroptotic necrotic cell death, since it is not inhibited by necrostatin-1. This process is characterized by an early generation of reactive oxygen species (ROS) resulting in p53 up-regulation. Accordingly, thiolic antioxidants protect cells from PES-induced death. Furthermore, inhibiting the natural sources of glutathione with l-buthionine-sulfoximine (BSO) strongly cooperates with PES in triggering cytotoxicity. Genetically modified p53-null or p53 knocked-down cells show resistance to PES-driven necrosis. The predominant localization of p53 in chromatin-enriched fractions added to the up-regulation of the p53-responsive gene p21, strongly suggest the involvement of a transcription-dependent p53 program. On the other hand, we report an augmented production of ROS in p53-positive cells that, added to the increased p53 content in response to PES-elicited ROS, suggests that p53 and ROS are mutually regulated in response to PES. In sum, p53 up-regulation by ROS triggers a positive feedback loop responsible of further increasing ROS production and reinforcing PES-driven non-necroptotic necrosis.

Copyright © 2014 Elsevier Inc. All rights reserved.

Address: Pharmacology Unit, Departament de Medicina Experimental, Universitat de Lleida, IRBLLEIDA, Ed. Biomedicina 1, Av. Rovira Roure 80, 25198 Lleida, Catalunya, Spain.; Cell Death, Senescence, and Survival Group, Departament de Bioquímica i Biologia Molecular and Institut de Neurociències, Facultat de Medicina, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08193 Bellaterra, Catalunya, Spain.; Pharmacology Unit, Departament de Medicina Experimental, Universitat de Lleida, IRBLLEIDA, Ed. Biomedicina 1, Av. Rovira Roure 80, 25198 Lleida, Catalunya, Spain. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.